FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143407531> ?p ?o ?g. }

• W2143407531 endingPage "2518" @default.
• W2143407531 startingPage "2512" @default.
• W2143407531 abstract "Abstract Purpose: To optimally integrate epidermal growth factor receptor (EGFR) inhibitors into the clinical treatment of head and neck cancer, two important questions must be answered: (a) does EGFR inhibition add to the effects of radiochemotherapy, and (b) if so, which method of inhibiting EGFR is superior (an EGFR antibody versus a small molecule tyrosine kinase inhibitor)? We designed an in vivo study to address these questions. Experimental Design: Nude mice with UMSCC-1 head and neck cancer xenografts received either single, double, or triple agent therapy with an EGFR inhibitor (either cetuximab or gefitinib), gemcitabine, and/or radiation for 3 weeks. Tumor volumes and animal weights were measured for up to 15 weeks. Immunoblotting and immunofluorescent staining were done on tumors treated with either cetuximab or gefitinib alone. Results: The addition of an EGFR inhibitor significantly delayed the tumor volume doubling time, from a median of 40 days with radiochemotherapy (gemcitabine and radiation) alone, to 106 days with cetuximab and 66 days with gefitinib (both P &lt; 0.005). Cetuximab resulted in significantly less weight loss than gefitinib. Immunoblot analysis and immunofluorescent staining of tumors show that although levels of phosphorylated AKT and extracellular signal–regulated kinase were decreased similarly in response to cetuximab or gefitinib, cetuximab caused prolonged suppression of pEGFR, pSTAT3, and BclXL compared with gefitinib. Conclusions: EGFR inhibition, particularly with cetuximab, improves the effectiveness of radiochemotherapy in this model of head and neck cancer. The correlation of response with prolonged suppression of EGFR, STAT3, and BclXL offers the possibility that these may be candidate biomarkers for response." @default.
• W2143407531 created "2016-06-24" @default.
• W2143407531 creator A5012072077 @default.
• W2143407531 creator A5016522247 @default.
• W2143407531 creator A5019256445 @default.
• W2143407531 creator A5046132413 @default.
• W2143407531 creator A5047877371 @default.
• W2143407531 creator A5050985047 @default.
• W2143407531 creator A5082916383 @default.
• W2143407531 creator A5084941880 @default.
• W2143407531 creator A5085318253 @default.
• W2143407531 date "2007-04-15" @default.
• W2143407531 modified "2023-10-16" @default.
• W2143407531 title "Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy <i>In vivo</i>" @default.
• W2143407531 cites W1862136029 @default.
• W2143407531 cites W1939364580 @default.
• W2143407531 cites W1976421760 @default.
• W2143407531 cites W1977340600 @default.
• W2143407531 cites W1992183189 @default.
• W2143407531 cites W2026177159 @default.
• W2143407531 cites W2037395954 @default.
• W2143407531 cites W2044991100 @default.
• W2143407531 cites W2051227018 @default.
• W2143407531 cites W2056816200 @default.
• W2143407531 cites W2074937243 @default.
• W2143407531 cites W2083215308 @default.
• W2143407531 cites W2097584581 @default.
• W2143407531 cites W2099462532 @default.
• W2143407531 cites W2103134643 @default.
• W2143407531 cites W2110866673 @default.
• W2143407531 cites W2116401711 @default.
• W2143407531 cites W2129432386 @default.
• W2143407531 cites W2139819066 @default.
• W2143407531 cites W2144233480 @default.
• W2143407531 cites W2155384808 @default.
• W2143407531 cites W2160425081 @default.
• W2143407531 cites W2166864956 @default.
• W2143407531 cites W2167368130 @default.
• W2143407531 cites W2274041246 @default.
• W2143407531 cites W2731594918 @default.
• W2143407531 doi "https://doi.org/10.1158/1078-0432.ccr-06-2582" @default.
• W2143407531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17438112" @default.
• W2143407531 hasPublicationYear "2007" @default.
• W2143407531 type Work @default.
• W2143407531 sameAs 2143407531 @default.
• W2143407531 citedByCount "48" @default.
• W2143407531 countsByYear W21434075312012 @default.
• W2143407531 countsByYear W21434075312013 @default.
• W2143407531 countsByYear W21434075312014 @default.
• W2143407531 countsByYear W21434075312015 @default.
• W2143407531 countsByYear W21434075312016 @default.
• W2143407531 countsByYear W21434075312017 @default.
• W2143407531 countsByYear W21434075312020 @default.
• W2143407531 countsByYear W21434075312021 @default.
• W2143407531 crossrefType "journal-article" @default.
• W2143407531 hasAuthorship W2143407531A5012072077 @default.
• W2143407531 hasAuthorship W2143407531A5016522247 @default.
• W2143407531 hasAuthorship W2143407531A5019256445 @default.
• W2143407531 hasAuthorship W2143407531A5046132413 @default.
• W2143407531 hasAuthorship W2143407531A5047877371 @default.
• W2143407531 hasAuthorship W2143407531A5050985047 @default.
• W2143407531 hasAuthorship W2143407531A5082916383 @default.
• W2143407531 hasAuthorship W2143407531A5084941880 @default.
• W2143407531 hasAuthorship W2143407531A5085318253 @default.
• W2143407531 hasBestOaLocation W21434075312 @default.
• W2143407531 hasConcept C121608353 @default.
• W2143407531 hasConcept C126322002 @default.
• W2143407531 hasConcept C143998085 @default.
• W2143407531 hasConcept C150903083 @default.
• W2143407531 hasConcept C170493617 @default.
• W2143407531 hasConcept C207001950 @default.
• W2143407531 hasConcept C2776362946 @default.
• W2143407531 hasConcept C2776530083 @default.
• W2143407531 hasConcept C2777506169 @default.
• W2143407531 hasConcept C2778820342 @default.
• W2143407531 hasConcept C2779438470 @default.
• W2143407531 hasConcept C2779998722 @default.
• W2143407531 hasConcept C2780258809 @default.
• W2143407531 hasConcept C2780580887 @default.
• W2143407531 hasConcept C502942594 @default.
• W2143407531 hasConcept C526805850 @default.
• W2143407531 hasConcept C71924100 @default.
• W2143407531 hasConcept C86803240 @default.
• W2143407531 hasConceptScore W2143407531C121608353 @default.
• W2143407531 hasConceptScore W2143407531C126322002 @default.
• W2143407531 hasConceptScore W2143407531C143998085 @default.
• W2143407531 hasConceptScore W2143407531C150903083 @default.
• W2143407531 hasConceptScore W2143407531C170493617 @default.
• W2143407531 hasConceptScore W2143407531C207001950 @default.
• W2143407531 hasConceptScore W2143407531C2776362946 @default.
• W2143407531 hasConceptScore W2143407531C2776530083 @default.
• W2143407531 hasConceptScore W2143407531C2777506169 @default.
• W2143407531 hasConceptScore W2143407531C2778820342 @default.
• W2143407531 hasConceptScore W2143407531C2779438470 @default.
• W2143407531 hasConceptScore W2143407531C2779998722 @default.
• W2143407531 hasConceptScore W2143407531C2780258809 @default.
• W2143407531 hasConceptScore W2143407531C2780580887 @default.
• W2143407531 hasConceptScore W2143407531C502942594 @default.

• next